Value ad(imab)

Adimab LLC's VCs expect to be in the black starting next year thanks to the antibody company's three recent tech transfer deals, including one last week with Novo Nordisk A/S. Adimab hopes the deals will mark the start of a steady flow of dividend checks to its investors.

CEO Tillman Gerngross said Adimab's business development strategy from the start has been to deploy its yeast-based antibody discovery technology as widely as possible (see BioCentury, March 31, 2008)...